Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF).
BACKGROUND Depression and chronic heart failure ( CHF ) are common conditions , both of which are clinical ly and economically highly relevant . Major depression affects 20 - 40 % of CHF patients and predicts adverse outcomes in terms of quality of life , morbidity and mortality as well as health care expenditure , independent of other factors of prognostic relevance . AIMS The purpose of the MOOD-HF trial is to clarify whether antidepressant pharmacotherapy improves outcome in CHF patients , and if so by which mechanism(s ) . METHODS MOOD-HF is a prospect i ve , r and omised , double-blind , placebo-controlled , 2-armed , parallel-group multicenter trial investigating the effects of the serotonin re-uptake inhibitor ( SSRI ) escitalopram on morbidity and mortality ( primary endpoint ) , severity of depression , anxiety , cognitive function , quality of life and health care expenditure in 700 patients with symptomatic systolic CHF and major depression diagnosed by structured clinical interview . All patients will receive optimised pharmacotherapy for CHF . Duration of follow-up , including close safety monitoring , is 12 - 24 months from r and omisation . PERSPECTIVE MOOD-HF is the first prospect i ve r and omised controlled trial to assess the effects of antidepressant pharmacotherapy  on hard somatic endpoints , the mechanism(s ) of action of SSRI treatment , as well as safety in New York Heart Association functional class II-IV CHF patients . The results are expected to promote the development of evidence -based recommendations for managing depression in the context of CHF . TRIAL REGISTRATION ( IS RCT N.org ) . Identifier : IS RCT N33128015
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .